Lico-simstn

Lico-simstn has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 13, 2026: “RNA platform sustained gene silencing beyond the liver in mice”.

Intervention

1 paper studies it2 findingsUpdated Oct 21, 2026

1 new paper in 30 daysSee all 1 papers on lico-simstn

At a glance

The findings reach mice, none yet in people. 1 lab.

None of its findings points the other way.

1 lab

2 of 2 findings with company ties

Animals1

What did studies of lico-simstn find?

Studies of lico-simstn measured 2 outcomes: muscle hypertrophy and myostatin mRNA.

Muscle hypertrophy

upin cynomolgus monkeys1

1 study

Lico-simstn induces muscle hypertrophy in cynomolgus monkeys.
“and progressive muscle hypertrophy without adverse clinical, hematological, or biochemical findings.”
AnimalsmuscleTwo intravenous doses
RNA platform sustained gene silencing beyond the liver in mice
Molecular therapy. Nucleic acidsOct 21, 2026

Myostatin mRNA

downin cynomolgus monkeys1

1 study

Lico-simstn decreases myostatin mRNA in cynomolgus monkeys (∼90% myostatin mRNA knockdown; 60%-70% suppression of circulating myostatin protein through day 98).
“In cynomolgus macaques, two intravenous doses of LiCO-siMSTN achieved ∼90% myostatin mRNA knockdown”
AnimalsTwo intravenous doses
RNA platform sustained gene silencing beyond the liver in mice
Molecular therapy. Nucleic acidsOct 21, 2026

Latest

1 paper in 12 months

Molecular Therapy Nucleic AcidsNov 13

RNA platform sustained gene silencing beyond the liver in mice

One dose reduced target gene messages by more than 90% in several mouse tissues, with at least 50% silencing lasting six months.One dose reduced target gene messages by more than 90% in several mouse tissues, with at least 50% silencing lasting six months.

Mouse studyInterventions

Paper